Melanotan II

Plain-English version: Melanotan II is a small, lab-synthesized peptide that mimics a hormone your body already makes to control skin color. When it binds to pigment-cell receptors, those cells produce more of the dark pigment (eumelanin) that tans skin — so people inject it to go darker without spending as long in the sun or a tanning bed.

It was developed in the early 1990s by researchers at the University of Arizona who were studying photoprotection — the idea of triggering the skin's own pigment defense to lower skin-cancer risk without the UV damage that normally drives a tan. Chemically, Melanotan II is a cyclic (ring-shaped) shortened analog of α-MSH, the natural α-melanocyte-stimulating hormone. That ring structure makes it more stable and far more potent than the natural hormone.^[1]

The critical thing a newcomer needs to understand is the regulatory reality: Melanotan II has never been approved as a drug or cosmetic in any country. In the US, selling or marketing it for human use is illegal under the Food, Drug & Cosmetic Act, and the UK's MHRA, the EU, and Australia's TGA have all issued public warnings. Everything sold online labeled "Melanotan II" comes from unregulated suppliers with no quality oversight.

Don't confuse it with three related molecules

The naming here trips up almost everyone, so it is worth being precise:

• Melanotan II — the non-selective, unapproved peptide this page is about.
• Melanotan I (afamelanotide, brand name Scenesse) — a different molecule, not a "version 1" of the same thing. It is a linear analog that selectively targets the pigment receptor (MC1R) and is FDA-approved, but only for a rare light-sensitivity disease called erythropoietic protoporphyria — not as a cosmetic tanning agent.
• PT-141 (bremelanotide, brand name Vyleesi) — an FDA-approved drug for low sexual desire in women that was derived from Melanotan II by shifting its structure toward the MC4R receptor.^[1]

So Melanotan II sits at the center of a family that produced two approved medicines — but the parent compound itself remains unapproved and is the riskiest of the three.

Plain-English version: Your body has a set of "melanocortin" receptors — think of them as different switches on different cells. Natural α-MSH flips mainly the skin-pigment switch. Melanotan II is a blunter instrument: it flips several switches at once, which is exactly why it tans your skin and makes you nauseous, curbs your appetite, and causes erections.

Melanotan II is a non-selective melanocortin-receptor agonist — it activates MC1R, MC3R, MC4R, and MC5R.^[1] Each receptor sits on different tissue and produces a different effect:

• MC1R (on skin pigment cells): This is the intended target. Activating it drives melanocytes to make more eumelanin, the brown-black pigment responsible for tanning. Because the peptide stimulates the cells directly, some darkening can occur without UV — though sun or a tanning bed accelerates and deepens it.
• MC4R (in the brain): Activating this receptor in the hypothalamus triggers sexual arousal and suppresses appetite. This is the source of both the spontaneous-erection side effect and the weight loss some users report — and it is the receptor that was deliberately isolated to create PT-141.^[1]
• MC3R (metabolic tissue): Involved in energy balance and inflammation; its contribution to the overall effect profile is less well defined.
• MC5R (glands and other tissue): Involved in exocrine gland function; poorly characterized in humans.

The tanning effect is cumulative — pigment builds over days to weeks of repeated dosing and then fades gradually over weeks after stopping, as pigmented skin cells are naturally shed.

Why "it's just a tanning peptide" is misleading

Because Melanotan II is non-selective, there is no dose that isolates the tan. The same molecule that darkens skin is simultaneously acting on brain circuits and, per the case-report literature, on blood vessels and muscle. A safety review of unregulated α-MSH analogues catalogued exactly this problem: the systemic melanocortin activation produces a "sympathomimetic" stimulant-like reaction (racing heart, blood-pressure swings, nausea) on top of the tanning.^[3] The selective descendants — Melanotan I for MC1R, PT-141 for MC4R — exist precisely because narrowing the receptor target improves the safety profile that Melanotan II lacks.

Plain-English version: Melanotan II does produce a tan — users and case reports consistently confirm the skin darkens. But you should know that there are no completed, published human efficacy trials of Melanotan II itself. The controlled tanning-trial data people cite almost always belongs to a different molecule (Melanotan I). So the honest evidence grade for Melanotan II's benefits is: real-world reports and mechanism, not clinical proof.

Skin tanning and pigmentation

Claim: darkens skin with reduced UV. Mechanism: MC1R activation drives eumelanin synthesis (see above). Population & evidence level: This is where honesty matters most. The frequently cited human tanning-and-photoprotection studies — three small Phase 1 trials with roughly 4–12 subjects each showing a tan plus about 47% fewer sunburn cells and less UV needed to tan — were conducted on Melanotan I (afamelanotide), not Melanotan II.^[2] They establish that the melanocortin-tanning mechanism works in humans, but they cannot be attributed to Melanotan II. For Melanotan II specifically, the human evidence is observational: case reports and case series in unregulated users describe visible tanning but were never designed to measure efficacy.^[3] Effect size: not quantified in any controlled Melanotan II trial. Limitation: no RCT, no standardized dosing, and the same pigment stimulation that tans skin also darkens moles (see Side Effects).

Photoprotection (the original research goal)

Claim: more baseline melanin means more natural UV protection. Mechanism: eumelanin absorbs UV and scavenges free radicals, reducing UV-induced DNA damage. Evidence level: The photoprotection rationale is supported for the melanocortin class in the Melanotan I trials (fewer sunburn cells),^[2] but has never been demonstrated as a cancer-prevention benefit for Melanotan II. Limitation: this theoretical benefit is directly undercut by the fact that Melanotan II can darken and alter existing moles, potentially masking early melanoma — the opposite of the intended protective effect.^[5]

Sexual arousal

Claim: increases sexual desire and causes erections. Mechanism: MC4R activation in the brain. Evidence level: This effect is real enough that it drove drug development — researchers isolated the MC4R activity of Melanotan II to create PT-141 (bremelanotide), which went on to FDA approval (Vyleesi) for hypoactive sexual desire disorder in women.^[1] Limitation: in Melanotan II this shows up as an uncontrolled side effect, including unwanted spontaneous erections and, in reported cases, priapism. If sexual health is the goal, the approved MC4R-selective descendant is the rational choice, not the non-selective parent.

Appetite suppression and weight loss

Claim: reduces appetite. Mechanism: MC4R signaling in the hypothalamus, a well-established appetite-regulating pathway. Evidence level: reported by users and consistent with melanocortin biology, but not measured in any controlled Melanotan II trial. Effect size: generally modest and highly variable between individuals. Limitation: this is an incidental effect of a compound with a serious safety record — it is not a weight-loss therapy, and the peptides studied for fat loss are entirely different molecules.

Bottom line on benefits: Melanotan II reliably tans skin, and its melanocortin activity is genuine and important enough that it seeded two approved drugs. But for Melanotan II as sold, there is no controlled human trial showing that the tanning benefit outweighs its documented harms — and that asymmetry is the entire reason regulators have taken action against it.

Plain-English version and important caveat: The "doses" below are the amounts described in unregulated-use reports and community protocols — not clinically validated instructions, because no dosing study of Melanotan II has ever been completed. We publish them for harm-reduction and accuracy, not as an endorsement. A published poisoning case shows why the numbers matter: a man who injected 6 mg — which he described as about six times a typical starting dose — developed stimulant-like toxicity, a heart rate up to 146, and rhabdomyolysis (muscle breakdown) that required three days in intensive care.^[8]

Reported protocols by phase

Phase	Reported dose	Frequency	Typical duration
Assess tolerance	0.25 mg	Once, then observe	First dose
Loading	0.25–0.5 mg	Once daily (SC)	1–3 weeks, until desired pigment
Maintenance	0.5–1.0 mg	1–2× per week	As needed to hold the tan

Route is subcutaneous (into the fat under the skin). Many people dose in the evening because the nausea and facial flushing that peak 15–60 minutes after injection are easier to sleep through. Some protocols pair a short UV exposure with the loading phase to speed pigmentation, which also compounds the underlying mole and skin-cancer concerns.

The single most important dosing point: cumulative exposure is what the harm reports track. The renal-infarction case involved an estimated ~27 mg total over six months before a clot destroyed roughly half of one kidney.^[9] "Small daily doses" still add up.

Reconstitution math (worked example)

Melanotan II ships as a lyophilized (freeze-dried) powder, commonly a 10 mg vial, that must be mixed with bacteriostatic water before use.

• 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL.
• To draw 0.5 mg: 0.5 ÷ 5 = 0.1 mL, which is 10 units on a U-100 insulin syringe.
• To draw 0.25 mg: 0.25 ÷ 5 = 0.05 mL, which is 5 units — a very small, easy-to-misjudge volume.

Because these volumes are tiny, a small measurement error is a large dosing error — one of several reasons the dose-related toxicity reports exist. Use the peptide reconstitution calculator to double-check volumes, and the reconstitution guide for sterile technique.

Storage

• Lyophilized powder: store frozen (-20°C) for long-term, or refrigerated (2–8°C) for shorter periods.
• Reconstituted solution: refrigerate at 2–8°C and use within about 28 days; do not freeze once mixed.

See the peptide storage guide for full handling detail.

Plain-English version: This is the section that should drive your decision. Melanotan II has the most concerning documented safety record of any peptide covered on this site. Beyond the near-universal nausea and flushing, peer-reviewed case reports link it to melanoma, new and changing moles, muscle breakdown, and a destroyed portion of a kidney. Health authorities in four major jurisdictions warn against it. Nothing here is designed to alarm for effect — every serious item below is a published, citable human case.

Common, expected side effects

Effect	Frequency	Notes
Nausea	Very common	Dose-dependent; worst during loading and with the first doses; often eases with continued use
Facial flushing / body warmth	Very common	Appears 15–60 minutes after injection
Appetite suppression	Common, variable	MC4R-mediated; some users lose noticeable weight
Spontaneous erections (males)	Common	MC4R activation
Mole and freckle darkening	Common at typical doses	Can mask early melanoma — see below
Fatigue, yawning, headache	Common	Usually transient
Injection-site redness or soreness	Common	Mild and transient
Blood-pressure and heart-rate changes	Variable	Both increases and decreases reported; part of a sympathomimetic reaction[3]

Serious adverse events reported in the medical literature

These are not everyday occurrences, but each is a real, published case — and it is the existence of this literature, combined with an unregulated supply chain, that underpins the regulatory warnings:

• Melanoma and pigmented-lesion change: A case documented melanoma in situ (an early skin cancer) developing in a Melanotan user, underscoring the unproven safety of these unlicensed peptides.^[7] Separately, changes in existing moles have been directly linked to unlicensed "sun tan jab" use.^[5] Because the peptide darkens moles, it can obscure exactly the changes dermatologists rely on to catch melanoma early.
• Eruptive and atypical moles: α-MSH analogues can drive melanocyte proliferation, and cases describe the rapid emergence of new eruptive nevi^[4] and atypical (dysplastic-looking) melanocytic naevi appearing after Melanotan injection.^[6]
• Rhabdomyolysis and stimulant-like toxicity: A 6 mg subcutaneous dose produced sympathomimetic toxicity, tachycardia (heart rate up to 146), and rhabdomyolysis requiring three days of intensive care.^[8]
• Renal (kidney) infarction: An estimated 27 mg of Melanotan II over six months preceded a right renal infarction that killed roughly half the kidney; the authors proposed a thrombotic or direct-toxic mechanism.^[9]
• Sympathomimetic and neurological reactions: A review of unregulated melanotan use catalogued dosing and preparation uncertainty alongside reports of a sympathomimetic toxidrome and reversible encephalopathy.^[3]

Who should not use it (contraindications)

• Anyone with a personal or family history of melanoma, atypical mole syndrome, or many/dysplastic moles — this is the clearest absolute reason to avoid it.
• People with numerous existing moles (roughly >50) — the mole-masking risk makes cancer detection harder.
• Pregnant or breastfeeding individuals — no safety data.
• Anyone with cardiovascular disease, uncontrolled high blood pressure, or a history of arrhythmia or clotting/ischemic events — given the reported cardiovascular and thrombotic events.
• People with kidney or liver disease.
• Children and adolescents.

Drug interactions

• Other melanocortin agonists (PT-141, Melanotan I): do not stack — additive receptor activation.
• PDE5 inhibitors (sildenafil, tadalafil): additive effect on erections and a theoretical priapism risk.
• Antihypertensives and stimulants: unpredictable effects on blood pressure and heart rate.

What to do if something goes wrong

• Any new or changing mole, during or after use: see a dermatologist promptly. Do not assume the change is "just" pigment from the peptide.
• An erection lasting more than 4 hours (priapism): this is a urological emergency — go to the emergency department.
• Severe muscle pain with dark urine: get evaluated for rhabdomyolysis (creatine kinase and kidney function).
• Severe headache, vision changes, confusion, or chest pain: seek emergency care.
• When in doubt, stop. The case-report record is strong enough that discontinuation is the safest response to any concerning new symptom.

For broader context on evaluating research-compound risk, see Are Peptides Safe? and our overview of peptide side effects.

Plain-English version: There is no legitimate, quality-controlled source of Melanotan II for human use, because it is not an approved product anywhere. Every vial on the market comes from the unregulated "research chemical" trade, where purity, dose accuracy, and sterility are unverified — and contamination or a mislabeled dose is a documented, not hypothetical, risk.

Legal status (2026)

• United States (FDA): Not approved as a drug or a cosmetic. Marketing or selling it for human use is illegal under the Food, Drug & Cosmetic Act. It is sold only under "not for human consumption" research labeling.
• United Kingdom (MHRA): Has issued repeated public warnings that melanotan products are illegal to sell and unsafe, citing nausea, melanoma concerns, and quality problems.
• Australia (TGA): A prescription-only substance; unregulated importation and supply are restricted.
• European Union: Not authorized in any member state; national authorities have repeatedly warned against use.

Note the contrast with its approved relatives: PT-141 (Vyleesi) is an FDA-approved prescription drug, and Melanotan I (afamelanotide/Scenesse) is FDA-approved for a rare medical condition. Melanotan II is the odd one out — the parent molecule that never earned approval. For the full legal picture on research peptides generally, see Are Peptides Legal?

If you evaluate a product anyway: what quality would require

Even setting the legal and safety issues aside, no consumer can independently verify most of what matters. A minimally credible research product would carry:

• A third-party Certificate of Analysis (COA) with HPLC purity testing and mass-spectrometry identity confirmation, tied to the specific lot number.
• Endotoxin (LAL) testing — critical for anything injected.
• Proper packaging: lyophilized powder in a sealed, light-protected vial.

Treat as red flags: no COA (or a manufacturer's own COA rather than an independent lab's), pre-mixed liquid, prices far below market, and any "for human use" or health-claim labeling, which signals a non-compliant seller. The reality is that even a clean COA does not make an unapproved, non-selective melanocortin agonist safe — it only addresses contamination, not the compound's intrinsic risks.

Plain-English version: The melanocortin family Melanotan II belongs to produced two approved, better-targeted drugs. If you want the effect, the smarter path is almost always the selective, approved relative — not the blunt, unapproved parent.

Compound	Receptor target	Main effect	Approval status
Melanotan II	Non-selective (MC1R/3R/4R/5R)	Tanning + arousal + appetite loss + side effects	Not approved anywhere
Melanotan I (afamelanotide / Scenesse)	MC1R-selective	Pigmentation / photoprotection	FDA-approved for erythropoietic protoporphyria only
PT-141 (bremelanotide / Vyleesi)	MC4R-selective	Sexual arousal	FDA-approved for HSDD in women

The pattern is clear: each time researchers narrowed the receptor target, the risk profile improved and the compound became approvable. Melanotan II is what those refinements were designed to move away from. For a deeper side-by-side of the two tanning peptides, read Melanotan I vs Melanotan II; for the fuller tanning-peptide walkthrough, see our Melanotan II tanning guide.